en

Sign up
Investments involve risks and are not suitable for all investors.

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Bristol-Myers Squibb Co.
Search

Bristol-Myers Squibb Co.

Closed

Sector Healthcare

50.42 11.25

Neutral

Price update 26 Jul 2024, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

45.26

Max

50.6

Key metrics

By Trading Economics

Income

-14B

-12B

Sales

423M

12B

P/E

Sector Avg

14.05

79.786

EPS

-4.4

Profit margin

-100.092

Employees

34,100

EBITDA

-13B

-8.6B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+9.98 upside

Dividends

By Dow Jones

Next Dividend date

1 Aug 2024

Next Ex Dividend date

3 Oct 2024

Market Stats

By TradingEconomics

Market Cap

61M

82B

Previous open

39.17

Previous close

50.42

News Sentiment

By Acuity

48%

52%

112 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

43.15 / N/A Support & Resistance

Bristol-Myers Squibb Co. Chart

Related News

26 Jul 2024, 14:08 UTC

Earnings

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

DJ

Read

26 Jul 2024, 11:54 UTC

Earnings

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

DJ

Read

25 Apr 2024, 14:38 UTC

Earnings

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

DJ

Read

25 Apr 2024, 11:52 UTC

Earnings

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

DJ

Read

26 Jul 2024, 14:51 UTC

Earnings

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

DJ

Read

26 Jul 2024, 13:53 UTC

Earnings

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

DJ

Read

26 Jul 2024, 11:28 UTC

Earnings

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

DJ

Read

26 Jul 2024, 11:14 UTC

Earnings

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

DJ

Read

26 Jul 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

DJ

Read

26 Jul 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

DJ

Read

26 Jul 2024, 11:04 UTC

Earnings

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

DJ

Read

26 Jul 2024, 11:04 UTC

Earnings

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

DJ

Read

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q EPS 83c >BMY

DJ

Read

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Net $1.68B >BMY

DJ

Read

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

DJ

Read

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

DJ

Read

19 Jun 2024, 05:30 UTC

Top News
Acquisitions, Mergers, Takeovers

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

DJ

Read

28 May 2024, 22:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

DJ

Read

25 Apr 2024, 12:36 UTC

Earnings

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

DJ

Read

25 Apr 2024, 12:31 UTC

Acquisitions, Mergers, Takeovers

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

DJ

Read

25 Apr 2024, 11:31 UTC

Earnings

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

DJ

Read

25 Apr 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

DJ

Read

25 Apr 2024, 11:05 UTC

Earnings

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

DJ

Read

25 Apr 2024, 11:05 UTC

Earnings

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

DJ

Read

25 Apr 2024, 11:04 UTC

Earnings

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

DJ

Read

25 Apr 2024, 11:04 UTC

Earnings

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

DJ

Read

25 Apr 2024, 11:03 UTC

Earnings

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

DJ

Read

25 Apr 2024, 11:03 UTC

Earnings

Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch

DJ

Read

25 Apr 2024, 11:03 UTC

Earnings

Bristol-Myers Squibb 1Q International Revenue Relatively Flat at $3.4B >BMY

DJ

Read

25 Apr 2024, 11:02 UTC

Earnings

Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B >BMY

DJ

Read

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

9.98% upside

12 Months Forecast

Average 49.79 USD  9.98%

High 75 USD

Low 33.1 USD

Based on 15 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

15 ratings

4

Buy

9

Hold

2

Sell

Based on 15 analysts giving stock ratings to Bristol-Myers Squibb Co. - Dist in the past 3 months.

Technical Score

By Trading Central

43.15 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

All events are bullish.

Intermediate Term

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

112 / 369 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Other stocks from the sector

LLY

Eli Lilly and Co.

802.55

↓-2.25%

UNH

UnitedHealth Group Inc

569.62

↑ +1.64%

NVO

Novo Nordisk A-S

126.83

↓-0.63%

JNJ

Johnson and Johnson

160.55

↑ +0.48%

MRK

Merck & Co Inc.

125.13

↓-0.6%